Human Genome Sciences (NASDAQ: HGSI) is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs." The company focuses on drug development, as well as drug discovery and currently (as of 2008) has a pipeline of novel compounds in clinical development, including drugs to treat...
more
Human Genome Sciences (NASDAQ: HGSI) is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs." The company focuses on drug development, as well as drug discovery and currently (as of 2008) has a pipeline of novel compounds in clinical development, including drugs to treat such diseases as hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. It has historically pursued collaborations with other biotechnology and pharmaceutical companies, for development partnerships and technology licensing .
HGSI currently has three (3) drugs in Phase III human testing: LymphoStat-B (belimumab) for lupus, Albuferon for Hepatitis C, and Abthrax (raxibacumab) for anthrax disease. Results of the various human studies are to be reported starting in late 2008. Belimumab is being developed with Glaxo...
less
